The clearance of oxidative stress compounds is critical for the protection of the organism from malignancy, but how this key physiological process is regulated is not fully understood. Here, we found that the expression of GPRC5A, a well-characterized tumor suppressor in lung cancer, was elevated in colorectal cancer tissues in patients. In both cancer cell lines and a colitis-associated cancer model in mice, we found that GPRC5A deficiency reduced cell proliferation and increased cell apoptosis as well as inhibited tumorigenesis in vivo. Through RNA-Seq transcriptome analysis, we identified oxidative stress associated pathways were dysregulated. Moreover, in GPRC5A deficient cells and mouse tissues, the oxidative agents were reduced partially due to increased glutathione (GSH) level. Mechanistically, GPRC5A regulates NF-jB mediated Vanin-1 expression which is the predominant enzyme for cysteamine generation. Administration of cystamine (the disulfide form of cysteamine) in GPRC5A deficient cell lines inhibited c-GCS activity, leading to reduction of GSH level and increase of cell growth. Taken together, our studies suggest that GPRC5a is a potential biomarker for colon cancer and promotes tumorigenesis through stimulation of Vanin-1 expression and oxidative stress in colitis associated cancer. This study revealed an unexpected oncogenic role of GPRC5A in colorectal cancer suggesting there are complicated functional and molecular mechanism differences of this gene in distinct tissues.
Colorectal cancer (CRC) has the third highest incidence rate of all diagnosed cancers and is the third highest cause of cancer-related deaths worldwide. 1 CRC is believed to be positively related to chronic bowel inflammation. Inflammatory bowel disease (IBD) has two major forms, namely ulcerative colitis and Crohn's disease. 2 Patients with IBD have a threefold higher risk of CRC. Although the mechanism of colitisassociated cancer (CAC) is not fully elucidated, genetic alterations and aberrant protein modifications in inflamed colonic mucosa occurred before malignant lesions are observed. [2] [3] [4] One of the major causes of genetic instability and cancer associated protein post-translational modifications is the oxidative stress that is provoked by reactive oxygen species (ROS) and nitrogen species produced by inflammatory cells. [5] [6] [7] It is believed that cancer progresses as a consequence of antioxidant system impairment. 8 Inhibition of nitric oxide synthase (NOS) through a genetic or pharmaceutical approach can significantly attenuate colitis in animal models. 5 A growing number of reports have demonstrated that high oxidative stress increases the risk of developing of colorectal cancer. 9, 10 The glutathione (GSH)-associated metabolic system is considered a major mechanism for elimination of ROS through thiol-disulfide redox. 6 Gamma-glutamylcysteine synthetase (gGCS) is the rate-limiting enzyme for GSH synthesis, whose activity is inhibited by cystamine. 3 Vanin-1 (VNN1) has pantetheinase activity which is responsible for the production of pantothenate (vitamin B5) and cysteamine. 7 As the predominantly expressed Vanin gene isoform in the gut, Vnn1 deficient mice lack free cysteamine and exhibit tissue resistance to oxidative stress and reduced intestinal inflammation and colorectal cancer. [11] [12] [13] [14] [15] It suggests that Vnn1 mediated GSH production plays important roles in colitis and colitis-associated cancer, but how Vnn1 is regulated by any other signaling remains largely obscure.
G protein-coupled receptor family C Group 5 type A (GPRC5A), also known as RAIG1 or RAI3, is a retinoic acidinduced G protein-coupled receptor (GPCR). GPRC5A was originally identified in 1998 in a human oral squamous carcinoma cell line. 16 Our and others' results have shown that the expression of GPRC5A is reduced in human lung tumors, and knockout of this gene in mice results in higher rates of spontaneous lung cancer, suggesting it is a tumor suppressor in the lung. 17, 18 In lung tumors, GPRC5A negatively regulates oncogenic pathways. [19] [20] [21] In contrast to lung cancer, several studies demonstrated that GPRC5A was overexpressed in various types of cancer, including breast, gastric, liver and colon tumors. [22] [23] [24] [25] As these studies are largely clinical studies, the role of GPRC5A in tumor development in tissues other than lungs is not well elucidated.
In this study, we found that the mRNA level of GPRC5A was significantly higher in colorectal cancer tissue than in adjacent normal tissues. Gprc5a null mice developed less colorectal cancer lesions than wild-type (WT) littermates in an AOM-DSS induced CAC model. Knockdown or overexpression of GPRC5A in human colon cancer cell lines confirmed its oncogenic roles. Reduced oxidative stress was observed in Gprc5a-deficient mouse cancer tissue and human cell lines with lower VNN1 expression and cystamine level. In summary, we discovered the unexpected oncogenic role of GPRC5A in colorectal cancer through VNN-1 induced oxidative stress.
Material and Methods

Patient specimens
Clinical CRC samples were obtained from Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. The subjects who participated in this study provided written informed consents. The tissue samples were collected and used after obtaining the approval from the Ethics Committee of Putuo Hospital. Fresh tissue samples of tumor and normal (defined as > 10.0 cm distance from tumor edge) colon tissues were collected from 57 CRC patients who underwent curative enterectomy between April 2009 and May 2010 at Putuo Hospital. The clinical pathological features of the patients are summarized in Supporting Information Table S1 . The fresh tissue samples were immediately stored in liquid nitrogen overnight and then frozen at 2808C until use. Animals C57BL/6 mice were purchased from the laboratory animal center, Shanghai, China. Gprc5a Knockout mice were generated as previously described. 17 All animal experiments conformed to the regulations drafted by Association for Assessment and Accreditation of Laboratory Animal Care in Shanghai and were approved by the Ethics Committee of East China Normal University.
What's new?
Colorectal cancer (CRC) is positively associated with chronic inflammation, a major feature of which is increased production of reactive oxygen species (ROS) that are capable of inducing potentially malignant changes in cells. Molecular pathways associated with those changes, however, have not been fully elucidated. Here, the retinoic acid-induced G protein-coupled receptor GPRC5A is identified as a potentially oncogenic player in CRC, whereby elevated GPRC5A expression leads to the dysregulation of pathways responsible for the clearance of oxidative agents. GPRC5A deficiency was associated with reduced cell proliferation in human cancer cell lines and with diminished tumor progression in mice.
Cell culture and RNA interference
Normal 293 T cell line and colorectal cancer cell lines HCT8 and HT29 were all purchased from the cell bank of Chinese academy of sciences. 293 T was maintained in DMEM (GIBCO), HCT8 was cultured in RPMI-1640 medium and HT29 grew in McCoy's 5a Medium. All these medium were supplemented with 10% fetal bovine serum (GIBCO). Cells were cultured at 378C with 5% CO2. The lentiviral-based knockdown was conducted using pLKO.1 vector. The shRNA oligos targeting human GPRC5A were listed in Supporting Information Table S2 . Each recombinant virus was harvested in 293 T cells. Human cancer cell lines were infected with shRNA lentiviruses and stable pool of cells were selected by supplement of 2 mg/ml puromycin in the medium.
Cell viability and apoptosis assays
Cell viability was measured by MTS which having the absorbance at 490 nm (Promega, WI). For apoptosis assay, cells were stained with FITC Annexin V and Propidium iodide (PI) according to the manufacture's protocol of FITC Annexin V Apoptosis Detection Kit (BD), and then analyzed by FACS. The PI and FITC double negative cells were counted as healthy cells. All assays were performed in triplicate and repeated three times independently.
Real-time RT-PCR
Total RNA was isolated from cells and cDNA was synthesized using the Prime Script RT-PCR Kit from Takara. Twostep real-time polymerase chain reaction was performed using SYBR Green Mix (Takara). The expression of the betaactin gene in each sample was used as an internal control. All the primers used were listed in Supporting Information (Table S2) .
Colony formation assay
Cells were plated in six-well plates and maintained in DMEM containing 10% FBS. After 2 weeks, the cells were fixed with paraformaldehyde and stained with 0.5% crystal violet. The numbers of colonies were counted under a microscope. After staining, the cells were washed three times with PBS and treated with 1 mL ethanol. The amount of crystal violet was measured by spectrophotometer with 590 nm wavelengths.
Colitis-associated colorectal cancer and DSS-induced inflammation models
The Gprc5a knockout mice were injected intraperitoneally with a single dose (12.5 mg/kg) of the mutagen azoxymethane (AOM) in 0.1 ml saline. 5 days after AOM administration, 2.5% (w/v) dextran sodium sulfate (DSS, molecular weight, 36-50 kilodaltons; MP Biomedicals, Irvine, CA) was administered in the drinking water for 5 days and then switched to normal drinking water for 14 days. This procedure was repeated for three cycles, followed by a switch to normal water.
RNA-seq and data analysis
Total RNA was isolated from the colorectal cancer tissues using the RNAeasy Mini Kit (Qiagen, Valencia, CA). Total RNA prepared was submitted to Shanghai Personal Biotechnology, where RNA intergrity was confirmed using the Illumina HiSeq 2000 system. Double-strand cDNA libraries were prepared and constructed using the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA). The synthesized cDNA libraries were diluted into 4-5 nM and sequenced. All Illumina-assembled unigenes were compared with the NCBI database (http://www.ncbi.nlm.nih.gov/), Ensembl (http:// www.ensembl.org/), KEGG database (http://www.genome.jp/ kegg) and eggNOG database (http://eggnog.embl.de/) using NCBI Blast (http://www.ncbi.nlm.nih.gov/).
Immunohistochemistry (IHC)
Sections were treated with standard procedure. For BrdU staining, a similar procedure was performed with the addition of a 30-min treatment with 2 N HCl at 378C after antigen retrieval. The number of positive cells in the 4003 field was quantitated for five fields of view per sample, and the average was calculated. 
Luciferase reporter constructs and assays
The human proximal VNN1 promoter (about 2 kb) was amplified by PCR from 293 T cell genomic DNA. PCR products were ligated into the pGL3 basic vector. The mutant human VNN1 promoter reporter construct (pGL3-VNN1-MUT) was different in the NF-jB binding site (-496, TTTCC > AAAGG) compared to the wild type human VNN1 promoter. HT29 cells were cultured in 48-well plates. After 18-20 h, 0.5 lg gene constructs were transfected in serumfree DMEM using lipofectamine 2000 (Thermo Fisher Scientific, MA). 36 to 48 hr after transfection, the luciferase activity was determined using the luciferase assay system (Promega) normalized to Renilla luciferase activity, as described. 26 
Measurement of intracellular ROS by flow cytometry
Cells were plated in 6-well plates at 1 3 10 5 cells per well and cultured for 24 hr. Cells were incubated with 10 mM DCFH-DA for 30 min. After that, a flow cytometer (BD, San Jose, CA) was used to measure the intensity of the cellular fluorescence. The excitation and emission wavelengths were set at 488 and 525 nm, respectively. Three independent experiments were performed.
Measurement of cystamine and glutathione and detection of c-GCS activity
Cells were seeded in 12-well plates at a density of 1.0 3 10 6 cells per well and cultivated for 24 hr. Cell suspension was Cancer Genetics and Epigenetics mixed with 600 lL of PBS. An equal volume of 1% metaphosphoric acid was added for 2 min. The cell suspension was then centrifuged at 13,000g for 10 min at 48C, and the supernatants were transferred into HPLC vials for cystamine and glutathione analysis, as described. 27, 28 The activity of g-GCS in cells and tissues was measured using g-GCS enzyme activity kit (Jiancheng Bioengineering Institute, Nanjing China).
Western blot analysis
The protein of colorectal cancer tissues or cells were harvested with the presence of Complete Mini Protease Inhibitor cocktail (Roche Diagnostic). Proteins extracts were quantified by Micro BCA TM Protein Assay Kit (Thermo Scientific) and denatured by the addition of sample buffer followed by boiling for 10 min, resolved by SDS-PAGE, and analyzed by Odyssey (Gene Company Limited). Primary antibodies: b-actin (1:5,000, Sigma), p-p65 (1:1,000, Abcam), p65 (1:1,000, Abcam), VNN1 (1:1000, Novus), p-IKBa (1:1000, CST), IKBa (1:1000, CST), Histone H3(1:1,000,CST), Tubulin(1:1,000, Epitomics-Abcam), PARP(1:2,000,CST), Bax(1:1,000,CST).
Statistical analysis
All data were presented as means with standard deviation (SD) or median with 95% confidence interval (95% CI). Statistic comparison was performed using the Student's t test, as appropriate, with the significance level at p < 0.05. Survival curve analysis was applied to analyze the relationship between GPRC5A expression status and clinical pathological status.
Results
GPRC5A is frequently up-regulated in human CRC samples
GPRC5A is considered to function as a tumor suppressor in lung cancer, but its expression is elevated in other malignant tumors, for example, in colorectal cancer. The intestinal epithelium is one of the two tissues besides lung tissue that have strong Gprc5a expression in mouse embryos. 17 However, the function of GPRC5A in the intestine is not well characterized. To determine the role of GPRC5A in colorectal cancer, the mRNA expression level of GPRC5A in CRC specimens was compared with adjacent normal tissues. After analysis of 57 pairs of samples from individual patients, the average expression level of GPRC5A was significantly increased (2.2-fold) in CRC specimens compared with adjacent normal tissues (p < 0.01; Fig. 1a ). 81% (46 of 57) patients exhibited GPRC5A upregulation in tumors compared to normal tissues in the same patient. The expression was upregulated in tumors by an average of 22-fold, in some cases over 150-fold. In the rest of 11 patients, GPRC5A mRNA level was downregulated in tumors in an average of 47.37%, with maximum 85.51% decrease (Fig. 1b) . Further statistical analysis suggested that the expression of GPRC5A was increased in Grade II tumor tissues, and with a further increase in Grade III/IV samples (Fig.  1c) . These results suggest that the expression of GPRC5A is significantly upregulated in colorectal cancer samples and is closely correlated with the tumor grades.
In order to study the association of GPRC5A expression in tumor with patient survival, we performed bioinformatic analysis of the NCBI-GEO database (Series GSE17538) 29 using Kaplan-Meier survival analysis. Dissecting the 244 colorectal cancer cases, we found there is a negative correlation between GPRC5A expression and the survival rate of the patients (p < 0.01) (Fig. 1d) , suggesting that high-expression of GPRC5A predicts poor prognosis in colorectal cancer patients.
Knockdown of GPRC5A suppressed colorectal cancer cell proliferation and colony formation while promoting apoptosis
We next examined GPRC5A expression in several colorectal cancer cell lines. The expression level of GPRC5A was highest in HT29 cells and lowest in the HCT8 cells (Supporting Information Figure 1a ). We then generated HCT8 subline overexpressing GPRC5A and HT29 subline with GPRC5A knockdown (Supporting Information Figs. 1b and 1c) . By using MTS and EdU staining method, we first determined the proliferation of these cell lines. Overexpression of GPRC5A enhanced the proliferation and DNA replication of HCT8 cells (p < 0.05; Figs. 2a and 2c left panel) and knockdown of GPRC5A decreased HT29 proliferation and DNA replication (p < 0.05; Figs. 2b and 2c right panel and Supporting Information Fig. 1d ). Then, we evaluated the colony formation of these cell lines. It was found that overexpression of GPRC5A enhanced HCT8 cell colony formation (Fig. 2d left) and knockdown of GPRC5A decreased HT29 cell colonies (Fig. 2d right) . Next, we examined cell apoptosis in HT29 cells and found that knockdown of GPRC5A increased Annexin V positive cell population (Fig. 2e ) which was further confirmed by increased protein levels of apoptotic associated genes such as cleaved Caspase3, PARP and Bax (Fig. 1f) .
Deletion of Gprc5a does not affect intestinal homeostasis
To determine the role of GPRC5A in colorectal tumorigenesis, we used Gprc5a -/-mice which were initially generated on a C57BL/6 background and no developmental abnormalities were observed as previously described. 17 Taking the advantage of the LacZ reporter driven by the endogenous Gprc5a promoter, 8 the expression of LacZ in intestinal tissue was examined by X-gal staining in heterozygous mice. Dense staining was observed in the colon epithelium, suggesting Gprc5a was expressed in epithelial cells in the large intestine (Supporting Information Fig. 2a ). Histology analysis showed no obvious morphological change in either the small or large intestine of Gprc5a -/-mice (Supporting Information Fig. 2b ). In addition, chromogranin-A immunohistochemistry and Alcian Blue staining for goblet cells showed no obvious changes between wild-type and Gprc5a -/-mice, suggesting that Gprc5a does not regulate large intestinal cell differentiation. Furthermore, cell proliferation in Gprc5a -/-mice colon was not affected, suggesting loss of Gprc5a does not affect cell proliferation and stem/progenitor cell populations under normal conditions in mice (Supporting Information Fig. 2c ).
To explore the role of Gprc5a in intestinal inflammation and tissue regeneration, Gprc5a -/-mice and wild-type littermates were subjected to the DSS-induced experimental IBD model. After DSS administration, there were almost no body weight or colon length differences between Gprc5a -/-mice and the wild-type controls, suggesting that Gprc5a does not affect tissue repair after acute injury (Supporting Information Figs. 2d  and 2e ).
Gprc5a deficiency inhibits colorectal tumorigenesis
To examine the role of Gprc5a in colorectal cancer, Gprc5a -/-and control littermates were subjected to experimental CAC induced by single injection of mutagen azoxymethane (AOM) followed by three rounds of oral administration of DSS (Fig.  3a) . As shown in Figure 3b , we observed tumor formation from the distal to the middle colon of both WT and mutant mice. In contrast to the WT control littermates, the average tumor load was lower and the average size was smaller in Gprc5a deficiency mice (p < 0.05; Fig. 3b ). Although the number of small tumors (diameter < 3 mm) was comparable, the number of large tumors (diameter > 3 mm) was dramatically lower in Gprc5a deficiency mice, suggesting that Gprc5a is potentially involved in tumor progression (Fig. 3b) . Histological analyses confirmed that low-grade tumor was present in Gprc5a -/-mice, while most of the tumors in control mice were high-grade tumors (p < 0.05; Fig. 3c ). BrdU incorporation assays were performed to analyze cell proliferation of tumors with similar size from WT and mutant mice (Fig. 3d left) . Sections from wild type mouse tumors had 52 6 11.47 BrdU1 cells per field whereas Gprc5a -/-mouse sections had 32.33 6 9.50, suggesting Gprc5a deficiency significantly reduced tumor cell proliferation (Fig. 3d) . As determined by TUNEL staining, cell apoptosis obviously increased in the Gprc5a -/-colorectal tumor compared to WT controls (p < 0.05; Fig. 3e ).
Transcriptome profiling analysis reveals Gprc5a deficiency impaired oxidative stress in tumors
In order to understand the mechanism underlying the oncogenic role of Gprc5a in colorectal cancer, RNA-Seq was employed to profile the differentially expressed genes in colorectal tumor tissues from WT and Gprc5a KO mice. We used a cutoff of twofold increase or 50% decrease in the expression levels and found significant changes in 123 genes out of 17,832 genes examined (p < 0.05). 83 genes were decreased and 40 genes increased expression in cancer tissue from Gprc5a KO mice. Gene Ontology (GO) analysis of the differentially expressed gene identified that immune/inflammatory response and redox metabolism was significantly influenced in Gprc5a deficient tumor tissues (Supporting Information Fig. 3 ). Since it was demonstrated that GPRC5A functioned in epithelial cell derived human colorectal cell lines, we focused on study the role of GPRC5A in oxidation-reduction process. Among these differentially expressed genes, we noted that 9 of them have been reported as indicators or regulators of oxidative stress ( Fig. 4a and see Discussion). We further validated these data by qPCR assays, suggesting that reduced oxidative stress occurred in Gprc5a null tumors (Fig. 4b) . We hypothesized that Gprc5a deficiency might decrease oxidative stress, resulting in reduced colorectal tumorigenesis. One of the most common oxidative lesions is 8-oxo-2'-deoxyguanosine (8-oxo-dG) that is an indicator of oxidantinduced DNA damage and oxidant status. 30 The promutagenic lesion, 8-oxo-dG, was detected in tumors by IHC. As shown in Figure 4c , 8-oxo-dG positive signals were dramatically reduced in Gprc5a deficient tumors compared with that of control tissues, indicating reduced oxidative DNA damage in tumor tissue with depletion of Gprc5a in colon.
To further confirm that Gprc5a regulates the cellular level of oxidants in colorectal cancer cells, intracellular ROS was detected by specific ROS marker DCFH-DA. 31 The fluorescent intensities of DCFH-DA (representing intracellular ROS levels) were evidently decreased in GPRC5A deficient HT29 cells (p <0.05; Fig. 4d ). Apparently, these argue that reduced ROS levels is not simply an artifact of delayed tumor induction, but is downstream result of GPRC5A activity. As GSH has a decisive effect on the intracellular redox status, we next determined the GSH level in both mouse CAC samples and human cell lines. The GSH concentration in CAC tissues of control littermates was 128.93 6 16.27 (mg/g total protein), whereas the GSH level in Gprc5a -/-samples was nearly twice as high (p < 0.01; Fig. 4e ). Similar results were found in HT29 cells with GPRC5A deficiency (Fig. 1f) . The above data suggested that the reduction of oxidative stress in GPRC5A deficient colorectal tumor cells was probably due to the increased GSH level.
GPRC5A regulates oxidative stress through VNN1
To understand how GPRC5A could regulate oxidative stress and GSH level, we first detected the expression level of enzymes involved in oxidative stress and GSH synthesis. We found that the expression of Copper/zinc superoxide dismutase (Sod1) and gamma-glutamylcysteine synthetase (g-Gcs) was unchanged compared with WT controls, but the expression of Vnn1 was dramatically decreased in Gprc5a deficient mouse tumor tissues or human cancer cells (Fig. 5a ). This data was also consistent with our RNA-Seq analysis and subsequent validation (Figs. 4a and 4b) . VNN1 is the predominant enzyme controlling the production of cysteamine in vivo. 17, 32 Consequently, we examined the cystamine content in CAC tissues and HT29 cells by HPLC. A significant decrease of cystamine level was detected in Gprc5a deficient tumor tissue and HT29 cells (Fig. 5b) . Cystamine is the disulfide form of cysteamine that inhibits g-GCS activity. 33, 34 To confirm that decreased cystamine level led to increased g-GCS activity in GPRC5A impaired cells, the enzyme activity was measured. As expected, the g-GCS activity was significantly increased in GPRC5A deficient cells or tumor tissues compared with that in controls (Fig. 5c) .
Administration of cystamine blocked the GPRC5A deficiency-induced phenotype in HT29 cells
The above data demonstrate that impaired GPRC5A in cells or tissues down-regulated VNN1 expression leading to reduced cysteamine biogenesis and elevation of g-GCS activity which can protect cells from oxidative stress. If this theory is reasonable, administration of cystamine could block GPRC5A deficiency-induced defects in cells. Thus, the culture medium of WT or GPRC5A impaired HT29 cells was supplemented with or without 10 lM cystamine, and the g-GCS activity was measured. Cystamine treatment significantly decreased g-GCS activity in GPRC5A deficient cells (Fig. 5d  left) . Furthermore, GSH levels in HT29 cells was increased in GPRC5A impaired cells but not in control cells. Cystamine treatment significantly decreased GSH level in GPRC5A deficient cells, suggesting that the increased GSH level in GPRC5A deficient cells was partially due to cystamine insufficiency (Fig. 5d right) . To examine whether cystamine treatment could block GPRC5A deficiency-induced cellular phenotypes, cells were treated with 10 lM cystamine for 48 h before MTS assays at different time points. The cell number was dramatically decreased in GPRC5A knockdown HT29 cells compared with controls. When treated with cystamine, the cell viability of GPRC5A deficient cells significantly increased, although still lower than WT controls (Fig. 5e) . Treatment of cystamine significantly decreased GPRC5A deficiency-induced cell apoptosis (Fig. 1f) . Additionally, we used colony formation assays to confirm that addition of cystamine in GPRC5A deficient HT29 cells increased cell viability using Spectrophotometer (Fig. 5g) . These data suggest that GPRC5A deficiency induced inhibition of cell proliferation and increased apoptosis in cancer cells through decreasing cellular cystamine production.
GPRC5A regulated the expression of VNN1 through the NFjB signaling pathway
In order to understand how GPRC5A regulates the mRNA level of VNN1, we analyzed the promoter region of VNN1 and found conserved NF-jB binding sites which may be involved in inflammation-associated gene expression (Fig.  6a) . We used tumor necrosis factor-alpha (TNF-a), a potent NF-jB activator inducing oxidative stress and nucleotide damage, 35 to stimulate the VNN1 promoter reporter. As shown in Figure 6b , the luciferase activity was not reduced in cells transfected with pGL3-VNN1-MUT reporter compared with that of pGL3-VNN1-WT construct in normal conditions. However, when the cells were challenged with TNF-a, the reporter activity of pGL3-VNN1-WT was strongly stimulated, but no induction was observed in cells transfected with the pGL3-VNN1-MUT construct (Fig. 6b) . This suggests that the NF-jB binding site may not determine VNN1 basal promoter activity, but is responsible for cytokine-induced VNN1 transcription. Furthermore, the expression of VNN1 mRNA significantly increased after treatment in HT29 cells, indicating that TNF-a stimulates endogenous VNN1 transcription (Fig. 6c) .
To explore the TNF-a/NF-jB signaling activity in GPRC5A deficient cells, we examined phosphorylated p65 (pp65) levels in tumor tissues with IHC or western blotting. In WT tumor sections, massive p-p65 positive signals were observed, especially in colonic epithelial cells. On the contrary, both the number and intensity of p-p65 positive signals were dramatically reduced in Gprc5a deficient tissue compared with that of WT controls (Fig. 6d) . Western blotting also suggested that p65 pathway activity was greatly reduced in Gprc5a mutant tumor tissues as both p-p65 and p-IKBa levels were decreased (Fig. 6e) . Consistent results were obtained in GPRC5A knockdown HT29 cell lines and VNN1 level was reduced coincidently with inhibition of p65 activity (Fig. 1f) . Specifically, nuclear localized active form of p-p65 was reduced in GPRC5A deficient HT29 cells (Supporting Information Fig. 4 ). These data suggest that GPRC5A regulates VNN1 expression through the modulation of cytokines, such as TNF-a, thereby inhibiting NF-jB mediated transcriptional regulation.
Discussion
Although the detailed molecular mechanism by which repeated colitis leads to colorectal cancer is not fully understood, it is well-accepted that chronic intestinal inflammation plays a major role in the initiation and progression of CAC. In this study, we found that increased expression of GPRC5A was positively correlated with colorectal tumor malignancy and a significantly poorer prognosis for patients. Deficiency of GPRC5A in human colon cancer cell lines or in mouse CAC models hampers cell proliferation and tumor progression, mainly through suppression of oxidative stress. Mechanistically, impaired GPCR5A signaling reduced cytokine-induced NF-jB activity leading to downregulation of VNN1 expression that resulted in accumulation of GSH to eliminate ROS in cells.
Our previous studies have shown that the expression of GPRC5A is dramatically reduced in non-small cell lung carcinoma. In addition, spontaneous lung tumors develop in aged Gprc5a knockout mice, demonstrating it is a tumor suppressor in lung cancer. 17 However, elevated expression of GPRC5A has been observed in breast cancer, 36 gastric cancer, 23 hepatocellular carcinoma 22 and colorectal cancer. 24 In this study, we confirmed that in the majority of patients the expression of GPRC5A is highly increased in colorectal tumor tissues compared with adjacent normal tissues (Figs. 1a and 1b). Although we do not have clinical data to investigate the correlation of GPRC5A expression with disease prognosis, we found that higher GPRC5A expression associated with poor prognosis by re-analysis of published data (Fig. 1d) . The GPRC5A mRNA level was strongly elevated in tumor tissue in 46/57 patients though slightly decreased in 11/57 patients, suggesting the oncogenic potential of GPRC5A in colorectal cancer. Tumorigenesis is a very complicated process in humans, so we used both human cell lines and knockout mice to investigate the role of GPRC5A in colon cancer. We found that Gprc5a deficiency reduced AOM/DSS-induced tumor load, especially the number of large tumors (Fig. 3b) . This could be due to the decreased cell proliferation and increased apoptosis in Gprc5a impaired tumors. Since no obvious defect was observed in Gprc5a knockout mouse intestinal tissues, including the tissue morphology, cell differentiation and proliferation (Supporting Information Figs. 2b and 2c) , the reduced tumor number and size in Gprc5a -/-mice are not due to imbalanced intestinal homeostasis. Additionally, we found that Gprc5a was not involved in acute inflammation response and tissue repair, since no significant difference was detected between the WT and Gprc5a knockout mice in DSS-induced colitis model (Supporting Information Figs. 2d and 2e ). All these data suggested that Gprc5a-specific effects in chronic inflammation induced colorectal cancer progression.
To investigate the molecular mechanism through which Gprc5a regulated tumorigenesis, we employed RNA-Seq and found numerous oxidative stress-associated genes were dysregulated (Figs. 4a and 4b and Supporting Information Fig. 3) . For example, H 2 O 2 stimulates the expression of natriuretic peptide C (NPPC) whereas N-acetylcysteine (NAC), a wellcharacterized antioxidant, inhibits it 37 ; the increased secretion of P-selectin (Selp) and E-selectin (Sele) appears to be triggered by an oxidative stress defense mechanism 38, 39 ; endoplasmic reticulum protein 27 (Erp27) and CD30 are induced during oxidative stress. 40, 41 The dysregulated expression of these target genes indicated that oxidative stress was reduced in Gprc5a knockout tumors, which was confirmed by the increased GSH level and reduced ROS (Figs. 4d and 4f ). Since all of the above genes were downstream targets expressed in response to oxidative stress, we hypothesized that Vnn1, the key player in regulation of GSH, was the major player downstream of Gprc5a during tumorigenesis. We confirmed that both the mRNA and the protein level were down-regulated in both GPRC5A deficient cells and mouse tissues. This suggests a model in which GPRC5a regulates VNN1 levels to inhibit cellular redox state.
As injection of cystamine has been shown to restore colitis susceptibility in Vnn1 knockout mouse, 13 we also showed that cystamine treatment restored GSH production in GPRC5A deficient cells (Fig. 5d) . Therefore, we believe that VNN1-mediated cystamine production is important in the Gprc5a pathway. In addition, we found that the expression of Vnn1 was responsive to TNF-a treatment potentially through an NF-jB binding site in its proximal promoter. Although NF-jB signaling is decreased in Gprc5a deficient tumors, it is unclear how Gprc5a regulates NF-jB activity. As we have shown that GPRC5A binds to EGFR to modulate its downstream signaling, 19 it will be interesting to investigate whether GPRC5A can bind to other membrane receptors to regulate NF-jB activation.
To our knowledge, this is the first evidence obtained in mouse models to demonstrate that GPCR5A plays an oncogenic role in tumor development, suggesting a complicated role of GPRC5A in tumor malignancy. Here we demonstrated that GPRC5A activates NF-jB pathway in colorectal cancer which is opposite from our previously study that GPRC5A inhibits NF-jB activation in lung injury and tumorigenesis. 20 It suggests that may due to GPRC5A differently regulates the same pathway in tissue type specific manner. As the lung and the digestive tract are the two major tissues with high GPRC5A expression in healthy mouse and humans, it will be interesting to explore the mechanism through which Gprc5a plays dual roles in tumorigenesis in different tissues. 42 In summary, we found that GPRC5A expression level was increased in colon tumor tissues and GPRC5A is associated with the development and progression of colorectal cancer through augmentation of oxidative stress by regulating NF-jB-induced VNN1 expression.
